Indian drugmaker Zydus Cadila said on Friday it signed a non-exclusive licensing pact with Gilead Sciences Inc to manufacture and market antiviral drug remdesivir, the first treatment to show improvement in COVID-19 trials. Zydus, listed as Cadila Healthcare, joins other Indian pharmaceutical companies Cipla Ltd, Jubilant Sciences Ltd and privately held Hetero Labs Ltd in signing non-exclusive pacts with Gilead for the drug. The drug, intravenously administered in hospitals, has already been approved for emergency use in severely-ill patients in the United States, India and South Korea.

from Yahoo Finance https://ift.tt/3hlTD6W

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]

from Yahoo Finance https://ift.tt/3fhgmiL

Nela Richardson, Edward Jones Investment Strategist, joins Yahoo Finance to discuss the market sell-off. She also weighs in on what investors can expect in the coming months as fears of a second wave of COVID-19 continue.

from Yahoo Finance https://ift.tt/3dYnkJf